Impact of Hepatitis B Virus Genotype on Treatment Response in Children With Chronic Hepatitis B

Summary

The study aimed to evaluate the relationship between hepatitis B virus genotype and treatment response in children with chronic hepatitis B with specific treatment indications. This is a prospective cohort study, with a follow-up period of at least 12 months, conducted at Children's Hospital 1 and City Children's Hospital, Ho Chi Minh City, Vietnam. The patient's blood was taken to be tested for hepatitis B virus genotyping using Sanger sequencing at the Center for Molecular Biomedicine Ho Chi Minh City. The research hypothesis is that genotype is related to treatment response.

Eligibility

Inclusion Criteria:

* Children from 2 years old to under 16 years old are diagnosed with hepatitis B chronic disease AND
* HBsAg or HBV DNA: positive for at least six months AND
* Liver enzyme ALT: continuously increased by\> 70 for male and \> 50 for female (\> 2 x ULN) AND
* The virus is proliferating: HBV DNA above 20,000 IU/mL (if HBeAg positive) OR HBV DNA above 2,000 IU/mL (if HBeAg negative) AND
* A parent or legal guardian of the pediatric patient obtains consent for them to participate in research.

Exclusion Criteria:

* HIV and hepatitis C co-infection
* Patients have other chronic liver disease (Wilson, autoimmune hepatitis)
* Patients are being treated with immunosuppressive drugs
* Psychomotor retardation, cerebral palsy, brain sequelae

Conditions2

Browse More Trials